Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.

The mechanistic target of rapamycin (mTOR) is an established therapeutic target in renal cell carcinoma (RCC). Mechanisms of secondary resistance to rapalog therapy in RCC have not been studied previously. We identified six patients with metastatic RCC who initially responded to mTOR inhibitor thera...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Lana Hamieh, Toni K Choueiri, Barbara Ogórek, Damir Khabibullin, Daniel Rosebrock, Dimitri Livitz, Andre Fay, Jean-Christophe Pignon, David F McDermott, Neeraj Agarwal, Wenhua Gao, Sabina Signoretti, David J Kwiatkowski
Format:	Artigo
Jezik:	Inglês
Izdano:	Public Library of Science (PLoS) 2018-09-01
Serija:	PLoS Genetics
Online dostop:	https://hdl.handle.net/10923/21647
Oznake:	Označite Brez oznak, prvi označite!